E3 Lithium Provides Notice of Annual General Meeting and Announces Director Nominations
CALGARY, Alberta--(BUSINESS WIRE)--E3 LITHIUM LTD. (TSXV: ETL) (FSE: OW3) (OTCQX: EEMMF), 'E3 Lithium' or the 'Company,' a leader in Canadian lithium, has set the Annual General Meeting (AGM) date to July 2, 2025.
AGM Details:
The Annual General Meeting of Shareholders will be held on Wednesday, July 2, 2025, at 10am. The Notice of the Meeting information will be distributed shortly to all shareholders, will also available under the Company's profile on SEDAR + (www.sedarplus.ca) and available on the Company website (www.e3lithium.ca/agm/). We look forward to any interested shareholders attending the AGM.
John Pantazopoulos, Chairperson of the Board of Directors (the 'Board') will be retiring from the Board and will not seek re-election at the AGM to pursue a career in public office. Mr. Pantazopoulos will serve as the Chairperson until the AGM and the Board will elect a new chair following the AGM. Over the past 2 years, in line with the Board's strategic planning, the Board has added three board members with diverse experience in the automotive industry, the lithium industry and government and policy. The number of directors will be set at five (5) with the incumbent directors nominated for the upcoming AGM.
Mr. Pantazopoulos has been a director of E3 Lithium since 2020 and has served as the CFO and Chairperson during that time. The Board of Directors and the Company's management team would like to thank John for his many years of service and valuable contributions to E3 and wish him well in his future in politics.
'I would like to thank John for his leadership and significant commitment to E3 Lithium over the years,' said Chris Doornbos, President and CEO. "John is running for city councillor Ward 6 in Calgary and we wish him the best this new endeavour. I will miss our regular conversations and appreciate the many contributions and sound advice he provided during some significant growth years at E3.'
ON BEHALF OF THE BOARD OF DIRECTORS
Chris Doornbos, President & CEO
E3 Lithium Ltd.
About E3 Lithium
E3 Lithium is a development company with a total of 16.2 million tonnes of lithium carbonate equivalent (LCE) Measured and Indicated 1 as well as 0.9 million tonnes LCE Inferred mineral resources 2 in Alberta and 2.5 million tonnes LCE Inferred mineral resources 3 in Saskatchewan. The Clearwater Pre-Feasibility Study outlined a 1.13 Mt LCE proven and probable mineral reserve with a pre-tax NPV8% of USD 5.2 Billion with a 29.2% IRR and an after-tax NPV8% of USD 3.7 Billion with a 24.6% IRR 1. E3 Lithium's goal is to produce high purity, battery grade lithium products to power the growing electrical revolution. With a significant lithium resource and innovative technology solutions, E3 Lithium has the potential to deliver lithium to market from one of the best jurisdictions in the world.
1: The Clearwater Project NI 43-101 Pre-Feasibility Study, effective June 20, 2024, is available on the E3 Lithium's website (www.e3lithium.ca/technical-reports/) and SEDAR+ (www.sedarplus.ca).
2: The mineral resource NI 43-101 Technical Report for the North Rocky Property, effective October 27, 2017, identified 0.9 Mt LCE (inferred) and is available on the E3 Lithium's website (www.e3lithium.ca/technical-reports/) and SEDAR+ (www.sedarplus.ca).
3: The mineral resource NI 43-101 Technical Report for the Estevan Lithium District, effective May 23, 2024, identified 2.5 Mt LCE (inferred) and is available on the E3 Lithium's website (www.e3lithium.ca/technical-reports/) and SEDAR+ (www.sedarplus.ca).
Unless otherwise indicated, Kevin Carroll, P. Eng., Chief Development Officer and a Qualified Person under National Instrument 43-101, has reviewed and is responsible for the technical information contained on this news release.
Forward-Looking and Cautionary Statements
This news release includes certain forward-looking statements as well as management's objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as 'may', 'will', 'plan', 'expect', 'anticipate', 'estimate', 'intend' and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of mineral exploration and development, fluctuating commodity prices, the effectiveness and feasibility of emerging lithium extraction technologies which have not yet been tested or proven on a commercial scale or on the Company's brine, competitive risks and the availability of financing, as described in more detail in our recent securities filings available at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Hi-View Clarifies Non-Brokered Private Placement
VANCOUVER, British Columbia, June 05, 2025 (GLOBE NEWSWIRE) -- HI-VIEW RESOURCES INC. ('HI-VIEW' OR THE 'COMPANY') (CSE: HVW; OTCQB: HVWRF; FSE: B63) Further to the Company's news release issued on May 28, 2025 announcing the non-brokered private placement, the Company further clarifies that the Company will rely on the exemption set out in Section 4.6(2)(b) of CSE Policy 4 - Corporate Governance, Security Holder Approvals and Miscellaneous Provisions (the "Policy") with respect to the requirement to obtain shareholder approval of such transaction whereby the Company is issuing more than 100% of its issued share capital on a fully diluted basis (relating to the Private Placement warrants). The Company applied and was granted by the CSE the exemption from shareholder approval based on the following: The Company is in financial hardship, has reached an agreement to complete the offering, no related persons as defined in Policy 1 will participate in the transaction; and has been approved by the majority of the independent directors of the Company. The non-brokered private placement will consist of up to 4,800,000 units (each a 'Unit') at a price of $0.10 per Unit for gross proceeds of up to $480,000 (the 'Private Placement'). Each Unit will consist of one common share (each, a 'Share') and one transferrable common share purchase warrant (each, a 'Warrant'). Each Warrant entitles the holder to purchase one additional Share of the Company at a price of $0.12 per Share for a period of 36 months from the date of issuance. Following closing of the Private Placement there will be 9,640,060 shares outstanding on a non-diluted basis. The net proceeds from the Placement will be allocated towards general corporate purposes including arm's length payables, exploration activities on its Toodoggone Projects. In accordance with the regulations of the Canadian Securities Exchange ("CSE"), an up to 10% finder's fees may be applicable. All securities issued pursuant to the Private Placement will be subject to a hold period of four months and one day as required under applicable securities legislation. About Hi-View Resources Inc. Hi-View is a mineral exploration company focused on the acquisition, exploration and development of mineral properties in Canada. The Company, through its subsidiary, holds a 100% interest in the Babine BC Copper-Gold property as well as interests in the Golden Stranger Property and the Lawyers East, West, South and BEN claims, located in the prolific Toodoggone region of northern BC, highly prospective for gold, silver, and copper. The collective holdings cover over 9,749 hectares. On Behalf of the Board of Directors, 'R. Nick Horsley'R. Nick Horsley, CEO For further information, please contact: Hi-View Resources Milne - PresidentEmail: hdmcap@ Telephone: (604) 377-8994Website: FORWARD LOOKING STATEMENTS: This news release includes certain statements that may be deemed 'forward-looking statements'. All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words 'expects', 'plans', 'anticipates', 'believes', 'intends', 'estimates', 'projects', 'potential' and similar expressions, or that events or conditions 'will', 'would', 'may', 'could' or 'should' occur. Forward-looking statements in this news release includes statements related to the proposed Transaction and related matters. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release. 1,2 AuEq in Thesis News Release dated Spetember5th, 2024 is defined in the mineral resources as being Au=Ag/ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
44 minutes ago
- Yahoo
[Latest] Global Internet of Medical Things IoMT Market Size/Share Worth USD 1061.49 Billion by 2034 at a 16.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Internet of Medical Things IoMT Market size & share revenue was valued at approximately USD 242.80 Billion in 2024 and is expected to reach USD 276.85 Billion in 2025 and is expected to reach around USD 1061.49 Billion by 2034, at a CAGR of 16.1% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Boston Scientific Corporation, General Electric Company (GE Healthcare), Johnson & Johnson Services Inc., Medtronic, Koninklijke Philips N.V., Siemens Healthineers AG, Cisco, IBM, Baxter (Hill-Rom Services Inc.), BIOTRONIK, and others. Austin, TX, USA, June 05, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'Internet of Medical Things (IoMT) Market Size, Trends, and Insights By Offering Type (General Purpose Reloadable Card, Gift Cards, Incentive/Payroll Card, Others), By Card Type (Closed Loop Prepaid Card, Open Loop Prepaid Card), By End User Industry (Retail, Healthcare, Travel and Hospitality, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database. 'According to the latest research study, the demand of the global Internet of Medical Things IoMT Market size & share was valued at approximately USD 242.80 Billion in 2024 and is expected to reach USD 276.85 Billion in 2025 and is expected to reach a value of around USD 1061.49 Billion by 2034, at a compound annual growth rate (CAGR) of about 16.1% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global Internet of Medical Things (IoMT) Market @ Internet of Medical Things IoMT Market Overview As per the industry experts at CMI, The global Internet of Medical Things (IoMT) market is growing rapidly due to increasing demand for connected healthcare and real-time monitoring. Leading players like Medtronic, GE Healthcare, Philips, Boston Scientific, and Johnson & Johnson are advancing smart devices and AI-powered diagnostics. These businesses position themselves on interoperable and secure platforms for optimized data exchange to participate effectively in healthcare value chains. Governments and healthcare systems unite with IoMT to provide chronic disease management for aging populations. Digital technology companies, in partnership with IoMT, to accelerate innovation and entry into the market. Relationships with technology (such as 5G, artificial intelligence, and edge technology) enable these products to improve and respond. As the market develops, these companies begin to target expansion outside of the national borders and employ a total digital healthcare ecosystem. Internet of Medical Things IoMT Market Growth Factors and Dynamics Increased Demand for Remote Patient Monitoring: Remote Patient Monitoring (RPM) uses connected medical devices to send health data to providers in real-time, thus allowing continuous care outside of clinical settings, thus benefitting chronic disease management and helping to support elderly care. Additionally, as Artificial Intelligence (AI) matures, the development of AI-enhanced RPM systems continues to be greatly anticipated. There are already AI-driven aspects of RPM, including the recognition of health deterioration early, personalized monitoring using federated learning, and behavior pattern identification through reinforcement learning. As these aspects matured, it offered an increased RPM capacity for health intervention, thereby improving patient outcomes. Thus, with the evolution of healthcare, RPM systems are quickly moving toward becoming in-demand and essential future healthcare technologies. It has been noted that RPM systems also reduce hospital readmissions, thus offering a cost-effective solution. Advancements in Wireless Technology: Advancements in wireless technology, such as 5G networks and low-power communication protocols have dramatically improved the functionality of Internet of Medical Things (IoMT) devices. These advancements offer faster data transmission, lower latency, and improved connectivity that make real-time monitoring and data analysis in the healthcare setting much more competent. Additionally, advancements in micro-computing and compact hardware allow for even greater innovation in the IoMT, enabling system innovations that now support timely diagnostics and remote monitoring of chronic conditions. But these advancements have also expanded the attack surface for security risks. Addressing these issues is necessary in order to protect patients and data integrity. Overall, the advancements in wireless technology are changing the way healthcare is delivered. Request a Customized Copy of the Internet of Medical Things (IoMT) Market Report @ Integration with AI and Big Data: The integration of Artificial Intelligence (AI) and Big Data analytics into Internet of Medical Things systems (IoMT) has disrupted the healthcare sector by enabling the processing of massive health datasets. Thus, it allows for predictive analytics, early detection of diseases, and highly individualized treatment plans. Likewise, AI-driven RPM systems are now able to detect early signs of patient decline, personalize monitoring through federated learning, and determine a patient's behaviors based on reinforcement learning. All of this enables years of proactive healthcare management, contributing to significant improvements in patient health. Furthermore, the system still provides a support role for healthcare providers and ultimately contributes to making healthcare better and more efficient. Report Scope Feature of the Report Details Market Size in 2025 USD 276.85 Billion Projected Market Size in 2034 USD 1061.49 Billion Market Size in 2024 USD 242.80 Billion CAGR Growth Rate 16.1% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Offering Type, Card Type, End User Industry and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the Internet of Medical Things IoMT report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the Internet of Medical Things IoMT report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the Internet of Medical Things IoMT Market Report @ Internet of Medical Things IoMT Market SWOT Analysis Strengths: The IoMT (Internet of Medical Things) market is based on the increased speed of connectivity, artificial intelligence, and sensor capabilities. The IoMT improves monitoring of patients, diagnosing, and treating; the evidence suggests improved health outcomes. Collecting and presenting data in real time helps improve clinical decisions and productivity. Adoption in existing healthcare systems (particularly in developed regions) continues to support the growth of the market. Innovation is also driven by the increased demand for remote care and wearables. Support from large healthcare providers, along with socio economic factors that support economic development, enables momentum for the IoMT. Weaknesses: The complex integration of many devices and many platforms persists as a principal issue related to IoMT. Substantial issues remain for patients and providers in terms of data security and privacy as well as cybersecurity risks. The upfront capital costs, complexity of adoption, and healthcare systems in many regions of the world (many with a lack of capital in developing regions) undermine the development of IoMT systems further. In specific instances, there may be regulatory barriers to market with IoMT devices and long periods without approval. In rural areas, internet connectivity issues may seriously inhibit the rollout of systems. The level of continuing education and digital literacy amongst staff in healthcare systems (e.g. nurses) can also inhibit the use of IoMT devices. Opportunities: The continued rollout of telemedicine services (e.g., telehealth) constitutes a significant opportunity for IoMT integration. The need for IoMT solutions is exacerbated by our aging population and chronic diseases, while there is the potential for investment in healthcare systems, particularly in emerging economies. The integration of artificial intelligence offers a market opportunity to drive predictive analytics and personalized healthcare. Partnerships are forming between technology firms, IoMT companies, and healthcare providers, which could lead to exciting innovations in the future; additionally, new government programs focused on digital health can help accelerate this process. Threats: A cybersecurity breach could result in catastrophic breaches of sensitive health data and loss of trust in any health system. A regulated market creates dependencies and appears to be an adversarial process, especially when compliance changes occur and regulatory delays arise. Continued lack of awareness of the myriad of devices joining the IoMT market is an insidious threat that can continue to undermine its potential. Competitive pressures are tremendous, increasing price risks and limiting profit margins. Other worsening economic drivers could reduce, limit, or void budgets and capital for healthcare IT. Traditional healthcare systems tend to be slow and resistant to changes, which increasingly protracts and limits adoption. Request a Customized Copy of the Internet of Medical Things IoMT Market Report @ Key questions answered in this report: What is the size of the Internet of Medical Things (IoMT) market, and what is its expected growth rate? What are the primary driving factors that push the Internet of Medical Things (IoMT) market forward? What are the Internet of Medical Things (IoMT) Industry's top companies? What are the different categories that the Internet of Medical Things (IoMT) Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the Internet of Medical Things (IoMT) market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium Internet of Medical Things (IoMT) Research Report | Fast Delivery Available - [220+ Pages] @ Internet of Medical Things IoMT Market Regional Perspective The Internet of Medical Things IoMT Market can be divided across different regions such as North America, Europe, Asia-Pacific, and LAMEA. This is a cursory overview of each region: North America: The emphasis in the United States in 2024 has been to minimize cybersecurity risks associated with healthcare IoT devices, and the United States Energy and Commerce Committee raised the need to mitigate risks to patients and providers from cyberattacks on health facilities, which could disrupt the continuum of care. The United States Department of Veterans Affairs has included funding in their FY 2025 budget for IT modernization and expansion of digital health technologies to improve the delivery of care for veterans. In Canada, investments from 2023 through the nation's health plan have resulted in further expansion of digital health services and favored the use of IoMT throughout the country. Europe: The United Kingdom has capitalized on stakeholder resources to implement IoMT solutions to advance the digital transformation of its National Health Service, increasing patient care while also enhancing the effectiveness of the health system. Germany's landmark legislation, the Digital Healthcare Act, which was passed in 2020, supports the referral of digital health applications and IoMT devices. Germany now enables reimbursement for the use of digital health applications and extends their use into clinical practice too. In Spain, telemedicine services are expanding via IoMT engagement, improving remote patient monitoring. Spain's digital healthcare strategy is targeting the improvement of access and quality care in rural and underserved regions within the care context of increasing healthcare access. Asia-Pacific: In 2024, India created new projects for the use of Artificial Intelligence (AI) to work with IoMT device data to improve diagnosis and patient monitoring and increase access to healthcare and reduce inefficiencies. China continues to make huge investments in order to create smart healthcare infrastructures that include IoMT technologies as part of China's rejuvenation modernization strategy to improve patient outcomes. At the same time, Japan is piloting the use of robots with IoMT devices to enhance healthcare delivery by employing them to assist with patient care and improve hospital efficiency. LAMEA: Brazil is developing digital health policies aimed at increasing awareness of IoMT device adoption to improve healthcare delivery and accessibility across the country. Countries in the Middle East and Africa are also integrating healthcare technologies, including IoMT, to improve medical services. Fueled by government policies and growing private investments, these regions are working towards modernizing their healthcare capabilities and disparities while increasing patient care through technologies. Request a Customized Copy of the Internet of Medical Things IoMT Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'Internet of Medical Things IoMT Market Size, Trends and Insights By Offering Type (General Purpose Reloadable Card, Gift Cards, Incentive/Payroll Card, Others), By Card Type (Closed Loop Prepaid Card, Open Loop Prepaid Card), By End User Industry (Retail, Healthcare, Travel and Hospitality, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at List of the prominent players in the Internet of Medical Things IoMT Market: Boston Scientific Corporation General Electric Company (GE Healthcare) Johnson & Johnson Services Inc. Medtronic Koninklijke Philips N.V. Siemens Healthineers AG Cisco IBM Baxter (Hill-Rom Services Inc.) BIOTRONIK Others Click Here to Access a Free Sample Report of the Global Internet of Medical Things IoMT Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: Data Center Rack Market: Data Center Rack Market Size, Trends and Insights By Rack Type (Open Frame Rack, Cabinet, Others), By Rack Height (Below 42 U, 42 U, Above 42 U), By Data Center Size (Large Data Centers, Small Data Centers, Mid-sized Data Centers), By End Users (BFSI, Government & Defence, Healthcare, IT & Telecom, Energy, Retail, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033 Data Center Fire Detection and Suppression Market: Data Center Fire Detection and Suppression Market Size, Trends and Insights By Systems (Fire Detection, Fire Suppression), By Deployment Location (In Data Cabinet, Technical Space/ Room Level, Building Level), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033 Equipment As a Service Market: Equipment As a Service Market Size, Trends and Insights By Equipment (Air Compressor, Pump, Power Tools, Ground Power Units, Laser Cutting Machines, Printing Machines, CNC machines, Material handling system, Packaging Machine, Excavators, Cranes, Others), By Service Model (Pay-per-Use, Subscription-Based, Leasing, Managed Services), By End Use (Construction, Material Handling, Mining, Manufacturing, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033 Consumer Identity and Access Management Market: Consumer Identity and Access Management Market Size, Trends and Insights By component (Solution, Services), By Solution Type (Identity Governance, Identity Analytics, Identity Administration and Authentication, Identity Proofing Services), By Services (Professional Services, Managed Services), By Deployment (On-premises, Cloud), By Authentication Method (Single Sign-On (SSO), Password less Authentication, Others), By End User Industry (BFSI, Hospitality & Travel, Healthcare, Retail & E-Commerce, Education, Government & Public Sector, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033 US Anime Market: US Anime Market Size, Trends and Insights By Type (T.V., Movie, Internet Distribution, Merchandising, Music, Pachinko, Live Entertainment, Others), By Genre (Action & Adventure, Sci-Fi & Fantasy, Romance & Drama, Sports, Others), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033 North America Virtual Influencer Market: North America Virtual Influencer Market Size, Trends and Insights By Type (Non-human, Human Avatar), By Offering (Solution, Services), By End-Use (Food & Entertainment, Sports & Fitness, Banking & Finance, Travel & Holiday, Fashion & Lifestyle, Others), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033 Artificial Intelligence in Banking Market: Artificial Intelligence in Banking Market Size, Trends and Insights By Component (Service, Solution), By Application (Fraud Detection and Prevention, Transaction Monitoring, Identity Verification, Customer Service, Virtual Assistants, Automated Customer Support, Risk Management, Credit Scoring, Market Risk Analysis, Personalized Banking, Customer Recommendations, Targeted Marketing, Compliance and Regulatory Reporting, Anti-Money Laundering (AML), Know Your Customer (KYC), Others), By Technology (Machine Learning, Supervised Learning, Unsupervised Learning, Reinforcement Learning, Natural Language Processing (NLP), Text Analysis, Speech Recognition, Chatbots and Virtual Assistants, Robotic Process Automation (RPA), Process Automation, Workflow Automation, Predictive Analytics, Risk Management, Customer Insights), By Enterprise Size (Large Enterprise, SMEs), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033 Custom Software Development Services Market: Custom Software Development Services Market Size, Trends and Insights By Deployment Mode (Cloud-based, On-Premises), By Solution Type (Web/desktop-based solutions, Mobile–Based Solutions, SME's, Large Enterprises), By End User (SME's, Large Enterprises), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033 The Internet of Medical Things IoMT Market is segmented as follows: By Product Stationary Medical Devices Implanted Medical Devices Wearable External Medical Devices By Application Telemedicine Medication Management Patient Monitoring By End-user Healthcare Providers Patients Government Authorities Click Here to Get a Free Sample Report of the Global Internet of Medical Things IoMT Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This Internet of Medical Things IoMT Market Research/Analysis Report Contains Answers to the following Questions. What Developments Are Going On in That Technology? Which Trends Are Causing These Developments? Who Are the Global Key Players in This Internet of Medical Things IoMT Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the Internet of Medical Things IoMT Market? What Was the Capacity, Production Value, Cost and PROFIT of the Internet of Medical Things IoMT Market? What Is the Current Market Status of the Internet of Medical Things IoMT Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of Internet of Medical Things IoMT Market by Considering Applications and Types? What Are Projections of the Global Internet of Medical Things IoMT Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is Internet of Medical Things IoMT Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On Internet of Medical Things IoMT Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of Internet of Medical Things IoMT Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for Internet of Medical Things IoMT Industry? Click Here to Access a Free Sample Report of the Global Internet of Medical Things IoMT Market @ Reasons to Purchase Internet of Medical Things IoMT Market Report Internet of Medical Things IoMT Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. Internet of Medical Things IoMT Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. Internet of Medical Things IoMT Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. Internet of Medical Things IoMT Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global Internet of Medical Things IoMT market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium Internet of Medical Things IoMT Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide Internet of Medical Things IoMT market analysis. The competitive environment of current and potential participants in the Internet of Medical Things IoMT market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide Internet of Medical Things IoMT market should find this report useful. The research will be useful to all market participants in the Internet of Medical Things IoMT industry. Managers in the Internet of Medical Things IoMT sector are interested in publishing up-to-date and projected data about the worldwide Internet of Medical Things IoMT market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in Internet of Medical Things IoMT products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the Internet of Medical Things IoMT Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply client insights on aspects such as strategies for future estimation falls, forecasting or opportunities to grow, and consumer surveys. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium Internet of Medical Things IoMT Research Report | Fast Delivery Available - [220+ Pages] @ beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
an hour ago
- Yahoo
Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies
The dilated cardiomyopathy market is experiencing steady growth, driven by rising prevalence of heart failure, improved diagnostic techniques, and advancements in genetic testing. Increasing R&D investment in gene therapies and novel drug candidates is expanding treatment options. Additionally, greater awareness and screening initiatives are supporting earlier diagnosis and management. New York, USA, June 05, 2025 (GLOBE NEWSWIRE) -- Dilated Cardiomyopathy Market Witnesses Robust Growth During the Study Period (2020–2034) Amid Advancements in Cardiovascular Therapies | DelveInsight The dilated cardiomyopathy market is experiencing steady growth, driven by rising prevalence of heart failure, improved diagnostic techniques, and advancements in genetic testing. Increasing R&D investment in gene therapies and novel drug candidates is expanding treatment options. Additionally, greater awareness and screening initiatives are supporting earlier diagnosis and management. DelveInsight's Dilated Cardiomyopathy Market Insights report includes a comprehensive understanding of current treatment practices, emerging dilated cardiomyopathy drugs, market share of individual therapies, and current and forecasted dilated cardiomyopathy market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Dilated Cardiomyopathy Market Report According to DelveInsight's analysis, the total dilated cardiomyopathy market size in the 7MM was estimated to be nearly USD 464 million in 2023, and it is expected to grow positively by 2034. Amgen's CORLANOR (ivabradine) generated the second-highest revenue of USD 90.3 million in the US in 2023. In the 7MM, the total dilated cardiomyopathy prevalence was estimated to be approximately 3 million in 2023, of which the US accounted for around 45%. Prominent companies, including Bristol-Myers Squibb, Berlin Cures, Cumberland Pharmaceutical, Rocket Pharmaceutical, Solid Bioscience, and others, are actively working on innovative dilated cardiomyopathy drugs. These novel dilated cardiomyopathy therapies are anticipated to enter the dilated cardiomyopathy market in the forecast period and are expected to change the market. Some of the key dilated cardiomyopathy treatments include Danicamtiv (MYK-491), BC007, DYSCORBAN (ifetroban), REN-001, AVB-401, SGT-601, and others. Discover which new treatment for dilated cardiomyopathy is expected to grab the market share @ Dilated Cardiomyopathy Market Report Dilated Cardiomyopathy Overview Dilated cardiomyopathy is a chronic and progressive heart disorder marked by the enlargement of the left ventricle, which impairs the heart's ability to pump blood effectively and can result in heart failure. By definition, patients exhibit systolic dysfunction, though they may or may not show clear signs of heart failure. The clinical presentation can vary widely from no symptoms to advanced heart failure. Common symptoms include shortness of breath during exertion, fatigue, palpitations, general dyspnea, swelling in the limbs, and arrhythmias such as ventricular tachycardia and atrial fibrillation. While many cases are idiopathic, some result from external factors such as viral infections (e.g., myocarditis), exposure to toxins (like excessive alcohol or chemotherapy drugs), autoimmune conditions, or nutritional deficiencies. Approximately 50% of cases have a genetic or familial basis. Diagnosing dilated cardiomyopathy involves a structured process to detect abnormalities in heart structure and function and to exclude other possible causes of cardiac impairment. This typically includes a thorough clinical evaluation, imaging techniques, lab investigations, and genetic Cardiomyopathy Epidemiology Segmentation The dilated cardiomyopathy epidemiology section provides insights into the historical and current dilated cardiomyopathy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The dilated cardiomyopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalent Cases of Dilated Cardiomyopathy Total Diagnosed Prevalent Cases of Dilated Cardiomyopathy Gender-specific Cases of Dilated Cardiomyopathy Familial and Non-familial Cases of Dilated Cardiomyopathy Download the report to understand which factors are driving dilated cardiomyopathy epidemiology trends @ Dilated Cardiomyopathy Treatment Options Dilated Cardiomyopathy Treatment Market Currently, there is no cure for dilated cardiomyopathy, but various treatments are available to manage symptoms and reduce the risk of complications. The choice of treatment depends on the extent of the heart's dysfunction and the patient's specific symptoms. The primary goals of treating cardiomyopathy are to: Prevent the condition from worsening, Address and manage any underlying or contributing health issues, and Minimize complications, including the risk of sudden cardiac arrest (SCA), with the ultimate aim of helping patients maintain a normal quality of life. Pharmacological interventions commonly used include diuretics, inotropic agents, afterload reducers, beta-blockers, anticoagulants, and anti-arrhythmic drugs. Inotropic agents used in treatment include digoxin, dobutamine, dopamine, epinephrine, norepinephrine, vasopressin, and milrinone. Afterload-reducing drugs include ACE inhibitors such as captopril, enalapril, lisinopril, and fosinopril, as well as angiotensin receptor blockers (ARBs) like losartan. Milrinone is notable for its dual action as an inotropic agent and vasodilator. ACE inhibitors and ARBs have shown effectiveness in managing heart failure with reduced ejection fraction and are recommended for patients with DCM. Stronger anticoagulants, including warfarin, heparin, and enoxaparin, require careful dosage adjustments and regular blood monitoring. Amgen's CORLANOR (ivabradine), approved by the US FDA, is currently the only dilated cardiomyopathy treatment drug in its class in the U.S. It works by selectively inhibiting the If current in the sinoatrial node, thereby slowing heart rate without affecting myocardial contractility or ventricular repolarization. In April 2019, the FDA approved CORLANOR for treating stable, symptomatic heart failure due to DCM in pediatric patients aged 6 months to 18 years. Dilated cardiomyopathy is a progressive disorder marked by continual myocardial injury, structural changes, and declining cardiac function. Hence, there is an urgent need for new treatments for dilated cardiomyopathy that can halt or delay disease progression, prevent adverse cardiac remodeling, and preserve heart function over time. Learn more about the dilated cardiomyopathy treatment options @ Dilated Cardiomyopathy Treatment Guidelines Dilated Cardiomyopathy Emerging Drugs and Companies Several novel therapies are under development, including Bristol-Myers Squibb's Danicamtiv (MYK-491), Berlin Cures' BC007, Cumberland Pharmaceuticals' DYSCORBAN (ifetroban), Rocket Pharmaceuticals' REN-001, Solid Biosciences' AVB-401 and SGT-601, among others. Danicamtiv (MYK-491), developed by Bristol Myers Squibb, is an orally available small molecule aimed at enhancing cardiac contractility. It works by increasing the formation of myosin-actin cross-bridges during heart muscle contraction, while maintaining diastolic function. Since myosin is the motor protein responsible for contracting the heart muscle by interacting with actin, MYK-491 targets the fundamental biomechanical dysfunction seen in patients with systolic heart failure and dilated cardiomyopathy. In these conditions, the left ventricle is too weakened and enlarged to pump blood efficiently. By boosting myosin-actin interactions, MYK-491 seeks to improve cardiac performance. BC007, developed by Berlin Cures, is a DNA aptamer that neutralizes harmful autoantibodies targeting the beta-1 adrenoceptor—a key G-protein coupled receptor involved in regulating heart rate and contractile force. Delivered intravenously, BC007 is part of the company's APTACURES platform, which focuses on aptamers that bind to autoantibodies against GPCRs. Ifetroban, the active component of DYSCORBAN from Cumberland Pharmaceuticals, is a highly selective thromboxane receptor (TPr) antagonist. It is designed to block fibrotic and inflammatory pathways in the heart, especially those initiated by the absence of dystrophin protein. By inhibiting key molecular signals involved in inflammation and tissue scarring, ifetroban may help preserve cardiac function in patients at risk of fibrotic damage. The anticipated launch of these emerging dilated cardiomyopathy drugs are poised to transform the dilated cardiomyopathy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the dilated cardiomyopathy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about dilated cardiomyopathy clinical trials, visit @ Dilated Cardiomyopathy Pipeline Market Dilated Cardiomyopathy Market Dynamics The dilated cardiomyopathy market dynamics are anticipated to change in the coming years. The increasing prevalence of drug or alcohol abuse, cardiac muscle infections, and rising public awareness in the 7MM are anticipated to fuel the growth of the dilated cardiomyopathy market, supported by advances in device therapies such as ICD, CRT, and surgical interventions that significantly reduce mortality and hospitalization rates; furthermore, opportunities exist to enhance genetic screening for at-risk individuals, improve disease management, and develop novel therapies with better efficacy, duration of action, safety profiles, and biomarker identification. Furthermore, many potential therapies are being investigated for the treatment of dilated cardiomyopathy, and it is safe to predict that the treatment space will significantly impact the dilated cardiomyopathy market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the dilated cardiomyopathy market in the 7MM. However, several factors may impede the growth of the dilated cardiomyopathy market. Dilated cardiomyopathy is a heterogeneous condition with various underlying etiologies, clinical manifestations, and prognostic factors, making it difficult to develop standardized treatment approaches; it is challenging to diagnose due to its nonspecific symptoms and variable presentation, often leading to delays in diagnosis and treatment initiation, and despite advancements in therapy, curative options remain lacking, existing treatments primarily aim to alleviate symptoms and slow progression, while the condition is associated with a poor long-term prognosis, with survival rates below 50% at 10 years and many patients facing progressive heart failure, arrhythmias, and sudden cardiac death. Moreover, dilated cardiomyopathy treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the dilated cardiomyopathy market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the dilated cardiomyopathy market growth. Dilated Cardiomyopathy Report Metrics Details Study Period 2020–2034 Dilated Cardiomyopathy Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Dilated Cardiomyopathy Market Size in 2023 USD 464 Million Key Dilated Cardiomyopathy Companies Bristol-Myers Squibb, Berlin Cures, Cumberland Pharmaceutical, Rocket Pharmaceutical, Solid Bioscience, and others Key Dilated Cardiomyopathy Therapies Danicamtiv (MYK-491), BC007, DYSCORBAN (ifetroban), REN-001, AVB-401, SGT-601, and others Scope of the Dilated Cardiomyopathy Market Report Dilated Cardiomyopathy Therapeutic Assessment: Dilated Cardiomyopathy current marketed and emerging therapies Dilated Cardiomyopathy Market Dynamics: Conjoint Analysis of Emerging Dilated Cardiomyopathy Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Dilated Cardiomyopathy Market Access and Reimbursement Discover more about dilated cardiomyopathy treatment drugs in development @ Dilated Cardiomyopathy Clinical Trials Table of Contents 1. Dilated Cardiomyopathy Market Key Insights 2. Dilated Cardiomyopathy Market Report Introduction 3. Dilated Cardiomyopathy Market Overview at a Glance 4. Dilated Cardiomyopathy Market Executive Summary 5. Disease Background and Overview 6. Dilated Cardiomyopathy Treatment and Management 7. Dilated Cardiomyopathy Epidemiology and Patient Population 8. Patient Journey 9. Dilated Cardiomyopathy Marketed Drugs 10. Dilated Cardiomyopathy Emerging Drugs 11. Seven Major Dilated Cardiomyopathy Market Analysis 12. Dilated Cardiomyopathy Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight Related Reports Dilated Cardiomyopathy Pipeline Dilated Cardiomyopathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dilated cardiomyopathy companies, including Berlin Cures, AstraZeneca, Biohaven Pharmaceuticals, Tenaya Therapeutics, among others. Dilated Cardiomyopathy Epidemiology Forecast Dilated Cardiomyopathy Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted dilated cardiomyopathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Hypertrophic Cardiomyopathy Market Hypertrophic Cardiomyopathy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypertrophic cardiomyopathy companies including Bristol Myers Squibb, Cytokinetics, Novartis, Imbria Pharmaceuticals, Univar Solutions B.V., among others. Hypertrophic Cardiomyopathy Pipeline Hypertrophic Cardiomyopathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hypertrophic cardiomyopathy companies, including Cytokinetics, Imbria, Bristol-Myers Squibb, Tenaya Therapeutics, Lexeo Therapeutics, Inc., BioMarin, among others. Restrictive Cardiomyopathy Market Restrictive Cardiomyopathy Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key restrictive cardiomyopathy companies including GlaxSoSmithKline, Teva Pharmaceuticals, Cipla, Sun Pharmaceuticals, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter CONTACT: Contact Us Shruti Thakur info@ +14699457679 in to access your portfolio
